Peng Lu Sells 15,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $40.13, for a total transaction of $601,950.00. Following the completion of the transaction, the president owned 65,179 shares of the company’s stock, valued at approximately $2,615,633.27. This trade represents a 18.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peng Lu also recently made the following trade(s):

• On Tuesday, September 8th, Peng Lu sold 15,000 shares of Pharvaris stock. The shares were sold at an average price of $40.68, for a total value of $610,200.00.
• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The shares were sold at an average price of $34.00, for a total value of $10,200.00.

Pharvaris Stock Down 1.6%

NASDAQ PHVS traded down $0.61 during trading hours on Tuesday, hitting $38.25. 1,020,979 shares of the company were exchanged, compared to its average volume of 398,337. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -12.54 and a beta of -2.33. The company has a 50 day moving average of $35.20 and a two-hundred day moving average of $31.49. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities research analysts predict that Pharvaris N.V. will post -3.12 EPS for the current year.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. venBio Partners LLC acquired a new position in shares of Pharvaris during the 2nd quarter worth $160,569,809. Wellington Management Group LLP boosted its holdings in Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after buying an additional 274,034 shares in the last quarter. Commodore Capital LP boosted its holdings in Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after buying an additional 29,525 shares in the last quarter. 5AM Venture Management LLC acquired a new position in Pharvaris during the second quarter worth about $27,581,008. Finally, Seven Fleet Capital Management LP increased its holdings in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after buying an additional 457,804 shares in the last quarter.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ shares have gained about 10% over the past month after Phase 3 results showed that the extended-release formulation of deucrictibant reduced hereditary angioedema attacks by 83%. The data support the company’s plans to pursue regulatory submissions in 2027 and strengthen the outlook for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst price-target expectations have improved. The reported consensus target was raised approximately 20% to $59.77, while RBC recently increased its target to $62 and maintained an outperform rating. The broader analyst view remains favorable, with a consensus “Moderate Buy” rating and an average target near $60. Pharvaris NV consensus price target raised 20.08% to $59.77
• Neutral Sentiment: Institutional ownership trends have been supportive, with investors including BlackRock and Alyeska Investment Group building positions. This may provide additional demand, although the purchases reflect earlier reporting periods rather than a new catalyst.
• Negative Sentiment: Several insiders recently sold shares. Director Anne Lesage sold 30,000 shares for approximately $1.15 million, while CEO Berndt Modig sold 2,291 shares for about $90,000 and President Peng Lu sold 15,000 shares for roughly $602,000. Lu’s transaction was made to cover tax withholding on vested equity awards, which reduces its negative signal, but the volume of insider selling could still weigh on sentiment. Insider Selling: Pharvaris Insider Sells 30,000 Shares

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, September 8th. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Oppenheimer reaffirmed an “outperform” rating and set a $75.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Finally, Rosenblatt Securities set a $60.00 target price on Pharvaris in a research note on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pharvaris currently has an average rating of “Moderate Buy” and a consensus price target of $59.87.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.